Indicative questions for the final module control.

1. The main types of viruses that cause ARVI and their clinical characteristics.

2. Types of coronaviruses that affect the human respiratory system.

3.Structure of the SARS-CoV-2 virus.

4. Target cells of SARS-CoV-2 and mechanisms of interaction of the virus with these cells.

5. Classification of SARS-CoV-2 variants according to WHO recommendations.

6. Definition of the term coronavirus infection.

7. Classification of coronavirus infection depending on the course of the disease.

8.Definition of the term ARDS.

9.Give a clinical picture of moderate severe coronavirus infection.

10.Definition of COVID-19.

11.The main clinical symptoms of COVID-19.

12. Clinical variants of COVID-19.

13. Main signs of severe COVID-19.

14. Complications that lead to severe COVI-19.

15. General and specific laboratory diagnostics.

16. Serological diagnosis of COVID-19.

17. PCR as the main diagnostic method.

18.Rapid diagnosis of the disease. Advantages and disadvantages of tests.

19. Rapid tests for the detection of COVID-19.

20. Difference between antigen and antibody detection in the diagnosis of COVID-19.

21. Treatment tactics for mild severity.

22. Treatment tactics for moderate severity.

23. Severity of coronavirus infection and its features.

24. Indications for the use of antibacterial drugs.

25. Indications for hospitalization with coronavirus infection

26. Main clinical criteria for COVID-19.

27. Severity of infection and its differences.

28. Principles of treatment depending on the course of the disease.

29. The place of antiviral drugs in the treatment of COVID-19.

30.Indications for the use of oxygen therapy and mechanical ventilation.

31. Effectiveness of remdesivir.

32. Effectiveness of favipiravir.

33.The role of hydroxychloroquine in the treatment of coronavirus infection.

34. Studies on the use of convalescent plasma in the treatment of coronavirus infection.

35.Oxygen support and its features.

36. Main indications for hospitalization according to clinical criteria for patients with COVID-19 in the intensive care unit

37. Treatment algorithms for different courses of COVID-19 in the intensive care unit

38. The main complications caused by SARS-CoV-2 in patients with severe comorbidities and approaches to their treatment.

39. Conditions for determining contact patients with COVID-19.

40. Rules for monitoring and surveillance of contact persons.

41.Basic recommendations for caring for a patient with COVID-19 at home.

42. Principles of surface disinfection.

43. Rules for using non-contact disinfection methods.

44. Types of protective measures aimed at preventing COVID-19 infection.

45. Specific prophylaxis for COVID-19.

46. Contraindications to vaccination against COVID-19.

47. Areas of separation during quarantine depending on the epidemic situation.

48. Restrictions on the movement of people during quarantine.

49. Biological material to be tested in patients with clinical signs of coronavirus disease.

50. Composition of the transport medium used for transportation of samples of materials taken from patients.

51: Types of PPE for doctors and nurses who care for patients with coronavirus disease (COVID-19) during inpatient treatment.

52. Conditions of discharge from the hospital for patients with coronavirus infection.

53. Stages of preventing or limiting the transmission of infection in healthcare facilities.

54. Main measures aimed at preventing the spread of COVID-19 in the inpatient department.

55. Key measures to prevent the spread of COVID-19 in outpatient and polyclinic settings.

56. Main measures to prevent the spread of COVID-19 in the Emergency Medical Center.

57. Basic principles of surface cleaning.

58. Levels of risk in the workplace of employers and safety and health services.

59.Pathogenesis of CNS damage by SARS-CoV-2 virus.

60.Brief description of direct mechanisms of CNS damage (neurogenic and hematogenic pathways).

61.Brief description of indirect mechanisms of CNS damage (inflammatory-mediated damage, thrombotic damage, damage due to hypoxia and homeostasis).

62. Clinical manifestations of nervous system damage in COVID-19.

63.Long- Covid.

64. Approaches to neurological rehabilitation in patients with COVID-19.

65. Application of Neuroxon in clinical neurology.

66.Definition of acute COVID-19, persistent COVID-19, long-COVID-19.

67. The main pathogenetic mechanisms of cardiovascular disease in COVID19.

68. The main clinical symptoms of cardiovascular disease after acute COVID19.

69. Laboratory changes indicative of myocardial damage after acute COVID19.

70. Additional studies required to identify long-COVID with symptoms of cardiovascular damage.